Microvi announced today that they were awarded a grant from the National Institute of Environmental Health Services (NIEHS) to develop a new technology for efficient, environmentally friendly, and cost-effective hexavalent chromium (Cr(VI)) treatment.
Read MoreThe in silico platform reduces the cost and timeframe of drug development by reducing the need for iterative pre-clinical experiments and better directing clinical trials, while increasing the effectiveness of the therapeutics themselves.
Read MoreStudies completed over the past year, funded through a Phase II NIH grant, show unprecedented removal rates of 1,2,3-Trichloropropane (TCP) and co-contaminants using Microvi’s cometabolism treatment technology.
Read MoreAt the convention Microvi will be part of the Innovation Zone, a hub for the most promising biotech companies to exhibit their novel technologies. All of the companies in the zone have been competitively selected by the NIH or NSF to meet strict guidelines about their technologies and commercialization potential.
Read More
